Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Pennsylvania National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00028782 |
RATIONALE: Diagnostic procedures using EF5 to detect oxygen level and blood vessels in tumor cells may help to improve the way photodynamic therapy is given.
PURPOSE: This clinical trial is studying how well EF5 works in detecting oxygen level and blood vessels in tumor cells of patients who are undergoing photodynamic therapy for intraperitoneal or pleural cancer.
Condition | Intervention |
---|---|
Malignant Mesothelioma Metastatic Cancer Peritoneal Cavity Cancer |
Drug: EF5 Procedure: fluorescent antibody technique Procedure: immunohistochemistry staining method |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label |
Official Title: | The Detection of Tumor Hypoxia and Vascularity in Patients Undergoing Intraperitoneal Photodynamic Therapy |
Estimated Enrollment: | 80 |
Study Start Date: | October 2001 |
Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
Patients are followed at 2 weeks and at 30-45 days post EF5 infusion.
PROJECTED ACCRUAL: A total of 80 patients (50 with intraperitoneal malignancy and 30 with pleural malignancy) will be accrued for this study within 2.5 years. Patients are stratified by disease (intraperitoneal malignancy vs pleural malignancy).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Currently enrolled on 1 of 3 photodynamic therapy trials (UPCC-2997, UPCC-4997, or UPCC-05503)
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United States, Pennsylvania | |
Abramson Cancer Center of the University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104-4283 |
Study Chair: | Stephen Michael Hahn, MD | University of Pennsylvania |
Study ID Numbers: | CDR0000069134, UPCC-05901, NCI-4110, UPCC-IRB-702341 |
Study First Received: | January 4, 2002 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00028782 |
Health Authority: | United States: Food and Drug Administration |
malignant ascites peritoneal cavity cancer advanced malignant mesothelioma localized malignant mesothelioma recurrent malignant mesothelioma |
Digestive System Neoplasms Abdominal Neoplasms Recurrence Antibodies Digestive System Diseases Ascites Peritoneal Diseases |
Neoplasm Metastasis Mesothelioma Gastrointestinal Neoplasms Peritoneal Neoplasms Adenoma Immunoglobulins Neoplasms, Glandular and Epithelial |
Neoplastic Processes Neoplasms Neoplasms by Site |
Pathologic Processes Neoplasms by Histologic Type Neoplasms, Mesothelial |